Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the ability of long-duration low intensity therapeutic ultrasound (LITUS) to alleviate knee Osteoarthritis pain over a 24-week period.

The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from knee Osteoarthritis pain.

Secondary objectives are to assess the ability of LITUS to improve joint function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-Duration Ultrasound for Knee Osteoarthritis

NCT03800927

Osteo Arthritis Knee

COMPLETED NA

Pain Relief Effect of Low-intensity Continuous Ultrasound Stimulator for Knee Arthritis

NCT05657535

Osteoarthritis, Knee

COMPLETED NA

Wearable Therapeutic Ultrasound Study for Knee Osteoarthritis

NCT01993693

Knee Osteoarthritis

TERMINATED NA

Randomized Trial in knEe Osteoarthritis Using Low Intensity Ultrasound - Evaluating Feasibility (RELIEF)

NCT01623804

Knee Osteoarthritis

TERMINATED NA

Ultrasound Guided Intra Articular Injection of Platelet Rich Fibrin Versus Hyaluronic Acid As Means of Pain Relief in Patients with Moderate Degree Knee Osteoarthritis

NCT06797960

Knee Osteoarthritis

NOT_YET_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 24-week study to clinically evaluate the effectiveness of the wireless Sustained Acoustic Medicine (SAM) device combined with diclofenac on symptoms of patients suffering from knee osteoarthritis. The class-II device, sam®, has been FDA-cleared for home use. On the first day of the study, baseline data will be collected as patients report pain score before treatment. During the following 24 weeks, patients will self-apply their assigned treatment for the 4 hours daily. Each day of the study, pain scores will be recorded immediately before application of SAM device as well as at the completion of treatment. Assessments on quality of life \& function, depression \& anxiety, and sleep will be performed prior to the patient beginning the protocol, at 8 weeks, 16 weeks and at the conclusion of the protocol.

Over 300 subjects will be recruited from neighboring communities to the study sites. The study is designed to reach a target patient population which includes rural citizens and socioeconomic disadvantaged individuals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteo Arthritis Knee Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAM Ultrasound Device and Diclofenac Patch

Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 24 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3 megahertz(MHz) frequency and 0.132 watts/cm\^2 intensity.

Group Type EXPERIMENTAL

Sustained Acoustic Device with 2.5% Diclofenac Patch

Intervention Type DEVICE

Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

SAM Ultrasound Device and SAM Patch

Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 24 weeks combined with SAM patch (0% diclofenac).

Group Type ACTIVE_COMPARATOR

Sustained Acoustic Device with 0% Diclofenac Patch

Intervention Type DEVICE

Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.

Diclofenac Patch

Patients wear 2.5% diclofenac patch for 4 hours at least 5 days a week for 24 weeks combined.

Group Type ACTIVE_COMPARATOR

2.5% Diclofenac Patches

Intervention Type DRUG

Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.

SAM Patch

Patients wear 0% diclofenac patch for 4 hours at least 5 days a week for 24 weeks combined.

Group Type PLACEBO_COMPARATOR

SAM Patch

Intervention Type OTHER

Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sustained Acoustic Device with 2.5% Diclofenac Patch

Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

Intervention Type DEVICE

Sustained Acoustic Device with 0% Diclofenac Patch

Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.

Intervention Type DEVICE

2.5% Diclofenac Patches

Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.

Intervention Type DRUG

SAM Patch

Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ZetrOZ Ultrasound Device Wearable Ultrasound Device Long Duration Ultrasound LITUS Device Wearable Long Duration Low-Intensity Device ZetrOZ Ultrasound Device Wearable Ultrasound Device Long Duration Ultrasound LITUS Device Wearable Long Duration Low-Intensity Device

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have physician-diagnosed mild to moderate knee OA (OARSI atlas grades 1-2)
* Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
* Are between 50-85 years of age
* Report a frequent pain score between 4-7 (range: 0-10) during the week preceding enrollment
* Report that knee pain negatively affects quality of life
* Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study
* Are deemed appropriate by their physician or by the study site physician to participate.
* Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.
* Not use or initiate use of opioid and/or non-opioid analgesic medications.
* Be willing to discontinue any other interventional treatment modalities on the knee during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).

Exclusion Criteria

* Cannot successfully demonstrate the ability to put on and take off the device.
* Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.
* Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening.
* Is pregnant.
* Is a prisoner.
* Is non-ambulatory (unable to walk).
* Has a pacemaker.
* Has a malignancy in the treatment area.
* Has an active infection, open sores, or wounds in the treatment area.
* Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.
* Has a known neuropathy (disease of the brain or spinal nerves).
* Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).
* Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months.
* Are currently taking steroids.
* Have any contraindication to radiograph.
* Have a secondary cause of arthritis (metabolic or inflammatory).

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes